Gary Veron
Washington, District of Columbia, United States
165 followers
156 connections
About
For more than 20 years, Gary Veron has advised clients regarding the development…
Activity
-
Check out the latest episode of Pharma – The Last Word, where Deborah Cho sits down with Phil Katz to dive into the FDA’s evolving approach to…
Check out the latest episode of Pharma – The Last Word, where Deborah Cho sits down with Phil Katz to dive into the FDA’s evolving approach to…
Shared by Gary Veron
-
Tune in to the pharmaphorum podcast with Partner Alice Valder Curran for insights on what happens next in the IRA’s Drug Price Negotiation Program…
Tune in to the pharmaphorum podcast with Partner Alice Valder Curran for insights on what happens next in the IRA’s Drug Price Negotiation Program…
Shared by Gary Veron
-
Join Hogan Lovells Jessica Hanna, Spenser Karr, and Eva Schifini for an exciting webinar, "Understanding Due Diligence," in partnership with…
Join Hogan Lovells Jessica Hanna, Spenser Karr, and Eva Schifini for an exciting webinar, "Understanding Due Diligence," in partnership with…
Shared by Gary Veron
Experience
More activity by Gary
-
Together, we are honored to support our clients to make the world a healthier place. We are pleased to be named Regulatory Firm of the Year for the…
Together, we are honored to support our clients to make the world a healthier place. We are pleased to be named Regulatory Firm of the Year for the…
Shared by Gary Veron
-
Join us on Wednesday 18 September in Boston for our Global Life Sciences and Health Care Horizons series. The event series is designed to help…
Join us on Wednesday 18 September in Boston for our Global Life Sciences and Health Care Horizons series. The event series is designed to help…
Shared by Gary Veron
-
On August 20, 2024, the Federal Trade Commission (FTC) filed a comment letter in support of the Food and Drug Administration’s (FDA’s) June 2024…
On August 20, 2024, the Federal Trade Commission (FTC) filed a comment letter in support of the Food and Drug Administration’s (FDA’s) June 2024…
Shared by Gary Veron
-
Gene therapies are revolutionizing patient treatment, but navigating the legal landscape can be challenging. Our chapter in the Life Sciences and…
Gene therapies are revolutionizing patient treatment, but navigating the legal landscape can be challenging. Our chapter in the Life Sciences and…
Shared by Gary Veron
-
In a recent decision, the U.S. Supreme Court overturned the longstanding Chevron deference doctrine, potentially subjecting FDA decisions to…
In a recent decision, the U.S. Supreme Court overturned the longstanding Chevron deference doctrine, potentially subjecting FDA decisions to…
Shared by Gary Veron
-
Navigating the legal landscape of #lifesciences in #China? Our latest article explores the critical Chinese legal considerations for Out-Licensing…
Navigating the legal landscape of #lifesciences in #China? Our latest article explores the critical Chinese legal considerations for Out-Licensing…
Shared by Gary Veron
-
The FDA’s new draft guidance on Diversity Action Plans (DAPs) is here. It mandates DAPs for certain medical products and clinical studies to improve…
The FDA’s new draft guidance on Diversity Action Plans (DAPs) is here. It mandates DAPs for certain medical products and clinical studies to improve…
Shared by Gary Veron
-
We are proud to announce our continued recognition by Chambers and Partners USA as leaders in the life sciences and health care industry, achieving 8…
We are proud to announce our continued recognition by Chambers and Partners USA as leaders in the life sciences and health care industry, achieving 8…
Shared by Gary Veron
-
We are proud of our continued recognition by Legal 500 U.S. including a tier 1 ranking in the 'Healthcare' practice area for Life Sciences and tier 2…
We are proud of our continued recognition by Legal 500 U.S. including a tier 1 ranking in the 'Healthcare' practice area for Life Sciences and tier 2…
Shared by Gary Veron
-
Attending #BIO2024? Meet our team at the California Pavilion - Exhibit Hall 2625 or schedule a 1:1 to hear how we can support your business goals.
Attending #BIO2024? Meet our team at the California Pavilion - Exhibit Hall 2625 or schedule a 1:1 to hear how we can support your business goals.
Shared by Gary Veron
-
Efforts to curtail U.S. reliance on biotechnology companies in the People’s Republic of China (PRC) and prevent certain data of U.S. persons from…
Efforts to curtail U.S. reliance on biotechnology companies in the People’s Republic of China (PRC) and prevent certain data of U.S. persons from…
Shared by Gary Veron
-
The May edition of our newsletter highlights the most recent industry news, legal trainings, and upcoming events all in one place. Helping you stay…
The May edition of our newsletter highlights the most recent industry news, legal trainings, and upcoming events all in one place. Helping you stay…
Shared by Gary Veron
-
We are thrilled to launch our brand-new podcast, "Pharma - The last word." This series will delve into the dynamic and complex world of…
We are thrilled to launch our brand-new podcast, "Pharma - The last word." This series will delve into the dynamic and complex world of…
Shared by Gary Veron
-
On 10 April, the European Parliament adopted its position on the draft text on the revision of the European Union’s general pharmaceutical…
On 10 April, the European Parliament adopted its position on the draft text on the revision of the European Union’s general pharmaceutical…
Shared by Gary Veron
Other similar profiles
Explore more posts
-
Paul Fehlner
I’m confused by business antipathy for regulation. Good rules provide predictability and can help avoid liability. Regulations may sometimes go too far, but that doesn’t make the solution no more rulemaking. Business interests may see the end of the Chevron Doctrine as a rainbow leading to higher profits. That may be true, but maybe not so much for businesses as for lawyers: plaintiff lawyers seeking damages awards for worksite injuries, pollution, and other torts, and public interest lawyers suing businesses under subjective interpretation of laws previosusly clarified by administrative experts. And since this Court has clearly gutted the concept of stare decisis in American law, no reason that any loss should discourage any future lawsuit. The absence of an expert administrative function will generate chaos, legal sclerosis, and workers who are less productive from unsafe conditions and injuries. This seems like a careful what you wish for decision.
6 Comments -
Michael Okaty
Due to the #FDA's recent draft guidance on maintaining data integrity for the clinical and bioanalytical portions of bioavailability and bioequivalence studies, companies conducting these studies should be diligent in ensuring the integrity of the data that is generated and submitted to the FDA. For a complete overview of the FDA's draft guidance, check out the blog post below. #lifesciences #data
-
PharmChem, Inc. Drugs of Abuse Sweat Patch
SCRAM of California exclusively uses PharmChek® for 3 simple reasons: Enhanced Accountability: The Sweat Patch serves as a constant reminder for clients to adhere to their treatment plans, holding them accountable and reinforcing their dedication to sobriety. Judicial Guidance: PharmChek® empowers courts with detailed data, enabling judges to discern issues, setbacks, and achievements, leading to more informed and impactful client support. Demonstrated Sobriety: Clients utilizing the PharmChek® Sweat Patch exhibit higher rates of sustained sobriety, with the patch acting as a crucial tool in their journey toward lasting change and transformation. Learn how PharmChek® can help improve your drug testing program at the link below. https://lnkd.in/gEXved83 #PharmChek #DrugTesting #CourtFact
-
Peter Lando
Yikes! The U.S. Patent and Trademark Office recently asked for suggestions to accelerate and incentivize the commercialization of innovation, but specifically requested that these suggestions not mention the proposed March-In framework, which would misuse the Bayh-Dole Act to assert government price controls -- a clear departure from the long-established understanding that will result in deceleration and disincentive to commercialization of innovation.
-
Christopher Bruno
A major, published decision affecting ANDA litigation and related FDA regulatory requirements for branded pharmaceutical companies yesterday from the District of New Jersey. Judge Chesler found that Teva Branded had erred by listing patents covering the delivery mechanism for its drug (there, an inhaler). Big implications in a debate that till now has gone relatively untested. Thoughts on the decision? #fdalaw #iplaw #iplitigation #andalitigation #paragraphivlitigation #patentlitigation
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More